NCT00434070 - Clinical Trial References

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

Citation(s)

Akileswaran C, Lurie MN, Flanigan TP, Mayer KH
Lessons learned from use of highly active antiretroviral therapy in Africa. Clin Infect Dis. 2005 Aug 1;41(3):376-85. Epub 2005 Jun 30. Review.
Deeks SG, Grant RM
Sustained CD4 responses after virological failure of protease inhibitor-containing therapy. Antivir Ther. 1999;4 Suppl 3:7-11. Review.
Weiss L, Burgard M, Cahen YD, Chaix ML, Laureillard D, Gilquin J, Piketty C, Viard JP, Kazatchkine MD, Girard PM, Rouzioux C
Immunological and virological features of HIV-infected patients with increasing CD4 cell numbers despite virological failure during protease inhibitor-based therapy. HIV Med. 2002 Jan;3(1):12-20.

Comparison of the Development of Thymidine Analogue Mutations With CD4 Monitoring Alone Versus CD4 Monitoring Plus Viral Load Monitoring in Naive HIV-1 Individuals on First-Line Antiretroviral Therapy in Africa

Details for clinical trial NCT00434070

Clinical trial NCT00434070 - References